Insider Transactions in Q4 2021 at Ab Cellera Biologics Inc. (ABCL)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2021
|
Andrew Booth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+47.46%
|
$0
$0.32 P/Share
|
|
Dec 08
2021
|
Veronique Lecault Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+13.59%
|
$0
$0.19 P/Share
|
|
Dec 03
2021
|
Andrew Lo Director |
BUY
Open market or private purchase
|
Direct |
86,938
+50.0%
|
$1,217,132
$14.02 P/Share
|
|
Nov 30
2021
|
Veronique Lecault Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
83,333
+5.53%
|
$1,166,662
$14.96 P/Share
|
|
Nov 18
2021
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
224,500
+50.0%
|
$3,367,500
$15.03 P/Share
|
|
Nov 11
2021
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
202,960
+0.36%
|
$2,841,440
$14.76 P/Share
|
|
Nov 11
2021
|
Andrew Booth Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
14,000
+9.66%
|
$196,000
$14.61 P/Share
|
|
Nov 11
2021
|
Andrew Booth Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
53,500
+50.0%
|
$749,000
$14.74 P/Share
|